Boone Capital Management LLC acquired a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 378,010 shares of the company's stock, valued at approximately $14,727,000. Kodiak Sciences comprises about 3.4% of Boone Capital Management LLC's holdings, making the stock its 12th largest holding. Boone Capital Management LLC owned approximately 0.60% of Kodiak Sciences at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of KOD. California State Teachers Retirement System lifted its position in Kodiak Sciences by 1,358.9% during the first quarter. California State Teachers Retirement System now owns 29,396 shares of the company's stock valued at $1,121,000 after purchasing an additional 27,381 shares during the period. GSA Capital Partners LLP purchased a new stake in Kodiak Sciences in the second quarter worth approximately $1,072,000. The Manufacturers Life Insurance Company grew its position in Kodiak Sciences by 31.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 120,629 shares of the company's stock worth $4,598,000 after purchasing an additional 29,121 shares during the period. Swiss National Bank bought a new stake in Kodiak Sciences in the 1st quarter worth approximately $2,188,000. Finally, PSP Research LLC purchased a new stake in Kodiak Sciences during the 4th quarter valued at $543,000. 89.06% of the stock is currently owned by institutional investors.
Kodiak Sciences Trading Down 0.3%
KOD opened at $39.33 on Thursday. Kodiak Sciences Inc. has a 1-year low of $8.29 and a 1-year high of $47.84. The company has a market capitalization of $2.47 billion, a PE ratio of -9.39 and a beta of 2.21. The firm's 50 day simple moving average is $40.16 and its two-hundred day simple moving average is $35.89.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Equities analysts forecast that Kodiak Sciences Inc. will post -3.83 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
KOD has been the topic of several research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Kodiak Sciences in a report on Friday, July 10th. Wall Street Zen lowered Kodiak Sciences from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. HC Wainwright reiterated a "buy" rating and set a $58.00 price objective on shares of Kodiak Sciences in a research report on Monday, August 17th. Chardan Capital raised Kodiak Sciences from a "neutral" rating to a "buy" rating and increased their target price for the company from $14.00 to $61.00 in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kodiak Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $48.14.
Get Our Latest Stock Report on Kodiak Sciences
Kodiak Sciences Profile
(
Free Report)
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
